Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
Go back to Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.11 +0.11 (1.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.00 | 52 Week High | $9.23 | |||
| Open | $9.89 | 52 Week Low | $1.16 | |||
| Day High | $10.15 | P/E | N/A | |||
| Day Low | $9.76 | EPS | $-0.30 | |||
| Volume | 11,145,262 | |||||
